TY - JOUR
T1 - Exploring Evergreening
T2 - Insights from Two Medicines
AU - Moir, Hazel V.J.
N1 - Publisher Copyright:
© 2016 The University of Melbourne, Melbourne Institute of Applied Economic and Social Research
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Litigated pharmaceutical patents are a valuable source of data on how much inventiveness is required for a patent grant and what are the costs of patents. Although innovation is central to economic growth and the competitiveness of firms, there are few data about either the cost of granted patents or the quantum of inventiveness required for a patent. Two cases of litigated pharmaceutical patents allow investigation of two types of secondary ‘evergreening’ patents—new formulations and closely related chemical variants. Both lead to higher Pharmaceutical Benefits Scheme outlays, and in some cases, these can be substantial. There are clear policy implications.
AB - Litigated pharmaceutical patents are a valuable source of data on how much inventiveness is required for a patent grant and what are the costs of patents. Although innovation is central to economic growth and the competitiveness of firms, there are few data about either the cost of granted patents or the quantum of inventiveness required for a patent. Two cases of litigated pharmaceutical patents allow investigation of two types of secondary ‘evergreening’ patents—new formulations and closely related chemical variants. Both lead to higher Pharmaceutical Benefits Scheme outlays, and in some cases, these can be substantial. There are clear policy implications.
UR - http://www.scopus.com/inward/record.url?scp=85000785124&partnerID=8YFLogxK
U2 - 10.1111/1467-8462.12171
DO - 10.1111/1467-8462.12171
M3 - Article
SN - 0004-9018
VL - 49
SP - 413
EP - 431
JO - Australian Economic Review
JF - Australian Economic Review
IS - 4
ER -